(SGMO, BLUE)—From Feuerstein’s quasi-tongue-in-cheek list of 2014 biotech predictions: http://www.thestreet.com/story/12206235/1/22-biotech-stock-predictions-for-2014.html Gene therapy developer Sangamo BioSciences (SGMO) issues press release No. 689 claiming to cure HIV but still, no one believes them. Bluebird's (BLUE) gene therapy program, however, proves to be the real deal. I have a 10% BLUE weighting in the SI charity contest, although I don’t own it in my real-world portfolio.